Compare PGZ & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGZ | SPRO |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 71.6M |
| IPO Year | N/A | 2017 |
| Metric | PGZ | SPRO |
|---|---|---|
| Price | $9.96 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.9K | ★ 708.3K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 12.26% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $9.32 | $1.08 |
| 52 Week High | $10.64 | $3.08 |
| Indicator | PGZ | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 31.95 | 38.90 |
| Support Level | $9.84 | $1.10 |
| Resistance Level | $10.14 | $1.29 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 3.74 | 56.80 |
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.